BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37000356)

  • 21. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
    BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
    Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
    Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
    J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
    Livingston-Rosanoff D; Schumacher J; Vande Walle K; Stankowski-Drengler T; Greenberg CC; Neuman H; Wilke LG
    Clin Breast Cancer; 2019 Dec; 19(6):e741-e747. PubMed ID: 31300338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between HER2 expression before neoadjuvant treatment and RCB classification after surgical treatment in breast cancer].
    Ma YQ; Wang XR; Liu YP
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1169-1173. PubMed ID: 33152824
    [No Abstract]   [Full Text] [Related]  

  • 27. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Hou Y; Nitta H; Wei L; Banks PM; Portier B; Parwani AV; Li Z
    Breast Cancer Res Treat; 2017 Nov; 166(2):447-457. PubMed ID: 28799059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
    Garufi G; Carbognin L; Arcanà C; Parola S; Ventriglia A; Doronzo A; Garutti M; Orlandi A; Palazzo A; Fabi A; Bria E; Tortora G; Arpino G; Giuliano M; Del Mastro L; De Laurentiis M; Puglisi F
    Cancer Treat Rev; 2022 Nov; 110():102454. PubMed ID: 35987149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer.
    Ajmani GS; James TA; Kantor O; Wang CH; Yao KA
    Ann Surg Oncol; 2017 Oct; 24(11):3157-3166. PubMed ID: 28685357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
    Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.